Actimis Pharmaceuticals is a start-up biopharmaceutical company focused on the development of small molecule therapeutics for severe respiratory and inflammatory disorders. The company is a spin-off from the respiratory diseases therapeutic research portfolio of Bayer Healthcare AG. Its lead program focuses on a small molecule antagonist against the receptor CRTH2, for once-daily dosing in asthma and atopic disease. The company has two small molecule lead compounds at different stages of pre-clinical development for respiratory and inflammatory diseases. It also has three proprietary genomics targets in early discovery stages. The company s targets focus upon the biology of the chemokine superfamily, small proteins released from a variety of cells under a variety of both physiological and pathological conditions.